|
시장보고서
상품코드
2075846
감염증 치료제 시장 : 치료 유형별, 질환 적응별, 투여 경로별, 지역별Infectious Disease Therapeutics Market, By Therapeutic Type, By Disease Indication, By Route of Administration, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
감염증 치료제 시장은 2026년에 800억 4,000만 달러 규모에 달할 것으로 추정되며, 2033년까지 1,285억 2,000만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7.0%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 800억 4,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026-2033년까지 예측 기간의 CAGR: | 7.00% | 2033년 금액 예측: | 1,285억 2,000만 달러 |
세계 감염증 치료제 시장은 호흡기 감염증, 성매개감염(STI), 혈액 감염 등의 용도로 사용되는 항생제, 항바이러스제, 항진균제를 포함한 광범위한 치료제 범주를 아우르고 있습니다. 수요는 경구용 및 비경구용 제제의 사용 확대와 더불어, 보다 효율적이고 신뢰할 수 있는 솔루션에 대한 수요에 힘입어 증가하고 있습니다. 지속적인 기술 발전과 최종사용자의 요구 증가가 이 시장의 성장을 주도하고 있습니다.
시장 역학:
호흡기 감염증 및 성매개감염증(STI) 치료제 사용 확대, 최종사용자의 수요 증가, 그리고 효율성과 성능 향상에 대한 지속적인 노력이 전 세계 감염증 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 이용 가능한 선택의 폭이 넓어짐에 따라, 더 다양한 사용자층이 이러한 솔루션을 이용할 수 있게 되었습니다.
예를 들어, 각 기업은 경구제나 주사제 등 변화하는 요구 사항에 대응하기 위해 제품 포트폴리오를 확대하고 있습니다. 또한, 혁신 및 신기술 통합에 대한 투자 증가로 인해 예측 기간 동안 시장 참여자들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 감염증 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- '세계 감염증 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 감염증 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 감염증 치료제 시장 : 치료 유형별, 2026-2033년
제5장 감염증 치료제 시장 : 질환 적응증별, 2026-2033년
제6장 감염증 치료제 시장 : 투여 경로별, 2026-2033년
제7장 감염증 치료제 시장 : 지역별, 2026-2033년
제1장 경쟁 구도
제2장 섹션
KSM 26.07.10Infectious Disease Therapeutics Market is estimated to be valued at USD 80.04 billion in 2026 and is expected to reach USD 128.52 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.0% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 80.04 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 128.52 billion |
The global infectious disease therapeutics market covers a broad set of therapeutic type categories, including Antibiotics, Antivirals, and Antifungals, used across applications such as Respiratory Infections, Sexually Transmitted Infections (STIs), and Bloodborne Infections. Demand is supported by adoption among Oral, and Parenteral and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.
Market Dynamics:
Growing adoption across Respiratory Infections, and Sexually Transmitted Infections (STIs), rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global infectious disease therapeutics market. A wider range of available options is making these solutions accessible to a broader base of users.
For instance, companies are expanding their portfolios to address evolving requirements across Oral, and Parenteral. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global infectious disease therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., GSK plc, Merck & Co, Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Bayer AG, Takeda Pharmaceutical Company Limited, and AstraZeneca plc, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global infectious disease therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global infectious disease therapeutics market.
Detailed Segmentation:
- Global Infectious Disease Therapeutics Market, By Therapeutic Type (Revenue, USD Bn, 2021 - 2033)
- Antibiotics
- Antivirals
- Antifungals
- Vaccines
- Others
- Global Infectious Disease Therapeutics Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
- Respiratory Infections
- Sexually Transmitted Infections (STIs)
- Bloodborne Infections
- Gastrointestinal Infections
- Others
- Global Infectious Disease Therapeutics Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Topical
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- GSK plc
- Merck & Co, Inc.
- Johnson & Johnson
- Roche Holding AG
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AbbVie Inc.
- Bayer AG
- Takeda Pharmaceutical Company Limited
- AstraZeneca plc
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Therapeutic Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Infectious Disease Therapeutics Market By Therapeutic Type, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Antivirals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Antifungals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Infectious Disease Therapeutics Market By Disease Indication, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Respiratory Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Sexually Transmitted Infections (STIs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Bloodborne Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Gastrointestinal Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Infectious Disease Therapeutics Market By Route of Administration, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Parental
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Infectious Disease Therapeutics Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
